001     142870
005     20240229112532.0
024 7 _ |a 10.1038/s41586-018-0810-y
|2 doi
024 7 _ |a pmid:30568303
|2 pmid
024 7 _ |a 0028-0836
|2 ISSN
024 7 _ |a 1476-4687
|2 ISSN
024 7 _ |a altmetric:52899852
|2 altmetric
037 _ _ |a DKFZ-2019-00500
041 _ _ |a eng
082 _ _ |a 500
100 1 _ |a Hilf, Norbert
|b 0
245 _ _ |a Actively personalized vaccination trial for newly diagnosed glioblastoma.
260 _ _ |a London [u.a.]
|c 2019
|b Nature Publ. Group52462
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1554366896_21267
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kuttruff-Coqui, Sabrina
|b 1
700 1 _ |a Frenzel, Katrin
|b 2
700 1 _ |a Bukur, Valesca
|b 3
700 1 _ |a Stevanović, Stefan
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Gouttefangeas, Cécile
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 6
|u dkfz
700 1 _ |a Tabatabai, Ghazaleh
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Dutoit, Valerie
|b 8
700 1 _ |a van der Burg, Sjoerd H
|b 9
700 1 _ |a Thor Straten, Per
|b 10
700 1 _ |a Martínez-Ricarte, Francisco
|b 11
700 1 _ |a Ponsati, Berta
|b 12
700 1 _ |a Okada, Hideho
|b 13
700 1 _ |a Lassen, Ulrik
|b 14
700 1 _ |a Admon, Arie
|b 15
700 1 _ |a Ottensmeier, Christian H
|b 16
700 1 _ |a Ulges, Alexander
|b 17
700 1 _ |a Kreiter, Sebastian
|b 18
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 19
|u dkfz
700 1 _ |a Skardelly, Marco
|b 20
700 1 _ |a Migliorini, Denis
|b 21
700 1 _ |a Kroep, Judith R
|b 22
700 1 _ |a Idorn, Manja
|b 23
700 1 _ |a Rodon, Jordi
|b 24
700 1 _ |a Piró, Jordi
|b 25
700 1 _ |a Poulsen, Hans S
|b 26
700 1 _ |a Shraibman, Bracha
|b 27
700 1 _ |a McCann, Katy
|b 28
700 1 _ |a Mendrzyk, Regina
|b 29
700 1 _ |a Löwer, Martin
|b 30
700 1 _ |a Stieglbauer, Monika
|b 31
700 1 _ |a Britten, Cedrik M
|b 32
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 33
|u dkfz
700 1 _ |a Welters, Marij J P
|b 34
700 1 _ |a Sahuquillo, Juan
|b 35
700 1 _ |a Kiesel, Katharina
|b 36
700 1 _ |a Derhovanessian, Evelyna
|b 37
700 1 _ |a Rusch, Elisa
|b 38
700 1 _ |a Bunse, Lukas
|0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
|b 39
|u dkfz
700 1 _ |a Song, Colette
|b 40
700 1 _ |a Heesch, Sandra
|b 41
700 1 _ |a Wagner, Claudia
|b 42
700 1 _ |a Kemmer-Brück, Alexandra
|b 43
700 1 _ |a Ludwig, Jörg
|b 44
700 1 _ |a Castle, John C
|b 45
700 1 _ |a Schoor, Oliver
|b 46
700 1 _ |a Tadmor, Arbel D
|b 47
700 1 _ |a Green, Edward
|0 P:(DE-He78)9b97ca569bcb00dfda69382bc7261700
|b 48
|u dkfz
700 1 _ |a Fritsche, Jens
|b 49
700 1 _ |a Meyer, Miriam
|b 50
700 1 _ |a Pawlowski, Nina
|b 51
700 1 _ |a Dorner, Sonja
|b 52
700 1 _ |a Hoffgaard, Franziska
|b 53
700 1 _ |a Rössler, Bernhard
|b 54
700 1 _ |a Maurer, Dominik
|b 55
700 1 _ |a Weinschenk, Toni
|b 56
700 1 _ |a Reinhardt, Carsten
|b 57
700 1 _ |a Huber, Christoph
|b 58
700 1 _ |a Rammensee, Hans-Georg
|0 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
|b 59
|u dkfz
700 1 _ |a Singh-Jasuja, Harpreet
|b 60
700 1 _ |a Sahin, Ugur
|b 61
700 1 _ |a Dietrich, Pierre-Yves
|b 62
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 63
|e Last author
|u dkfz
773 _ _ |a 10.1038/s41586-018-0810-y
|g Vol. 565, no. 7738, p. 240 - 245
|0 PERI:(DE-600)1413423-8
|n 7738
|p 240 - 245
|t Nature
|v 565
|y 2019
|x 1476-4687
909 C O |p VDB
|o oai:inrepo02.dkfz.de:142870
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 48
|6 P:(DE-He78)9b97ca569bcb00dfda69382bc7261700
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 59
|6 P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 63
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NATURE : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b NATURE : 2017
920 1 _ |0 I:(DE-He78)L801-20160331
|k L801
|l DKTK Tübingen
|x 0
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 1
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 2
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 4
920 1 _ |0 I:(DE-He78)L501-20160331
|k L501
|l DKTK Frankfurt
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)L801-20160331
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L501-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21